Mei Pharma Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for cancer treatment. The company specializes in creating novel cancer drugs that target specific signaling pathways and mechanisms involved in tumor growth and progression. Through its commitment to research and development, Mei Pharma aims to advance its pipeline of drug candidates, with the goal of providing more effective treatment options for patients suffering from various types of cancer. Their approach includes both monotherapy and combination treatments, leveraging the latest scientific advancements to improve patient outcomes and quality of life. Read More
[UK, July 24, 2025] - BTC As the blockchain industry enters a new round of market cycle, the multi-currency linkage effect gradually emerges, and the price of BTC today starts to rise at 118875.30. According to foreign media reports such as Investing, with the continuous inflow of US spot ETF funds, the acceleration of technology implementation by the Ethereum Layer 2 Industry Alliance, and the launch of the network upgrade of Dogecoin (DOGE), Bitcoin's "safe-haven attribute" as a market value anchor has once again attracted capital favor, and its network computing power and BTC mining income have increased significantly.
MEI Pharma, Inc. (Nasdaq: MEIP) (the “Company” or “MEI”) today announced that it has closed its previously announced private placement for the purchase and sale of 29,239,767 shares of common stock (or pre-funded warrants in lieu thereof) at a price of $3.42 per share, for aggregate gross proceeds of approximately $100 million. In connection with the closing of the transaction, MEI has appointed Charlie Lee to its Board of Directors (at which time current member Taheer Datoo will resign) and GSR as its digital asset and treasury management advisor to oversee the implementation of its Litecoin Treasury Strategy.
MEI Pharma, Inc. (NASDAQ:MEIP) stock is trading higher on Friday, with a session volume of 35.64 million compared to the average volume of 29.8K, as per data from Benzinga Pro.
MEI Pharma intends to use the funds to acquire the native cryptocurrency of the Litecoin blockchain, commonly referred to as “LTC”, which will serve as the company’s primary treasury reserve asset.
MEI Pharma, Inc. (Nasdaq: MEIP) (the “Company” or “MEI”) today announced that it has entered into securities purchase agreements for a private investment in public equity (PIPE) for the purchase and sale of 29,239,767 shares of common stock (or pre-funded warrants in lieu thereof) at a price of $3.42 per share, for expected aggregate gross proceeds of approximately $100 million, before deducting placement agent fees and other estimated offering expenses. In connection with the closing of the transaction, MEI will appoint Charlie Lee to its Board of Directors (at which time current member Taheer Datoo will resign) and GSR as its digital asset and treasury management advisor to oversee the implementation of its Litecoin Treasury Strategy.
MEI Pharma, Inc. (Nasdaq: MEIP) (the “Company”) today announced that it has engaged Oppenheimer & Co. Inc. to serve as the Company’s exclusive financial advisor to assist in its previously announced process to review and evaluate strategic alternatives. The Company remains focused on maximizing the value of its assets for its stockholders.
